scispace - formally typeset
D

David A. Kass

Researcher at Johns Hopkins University School of Medicine

Publications -  605
Citations -  63963

David A. Kass is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Heart failure & Cardiac resynchronization therapy. The author has an hindex of 127, co-authored 580 publications receiving 58747 citations. Previous affiliations of David A. Kass include University of Pittsburgh & Johns Hopkins University.

Papers
More filters
Journal ArticleDOI

Evaluation of contractile state by maximal ventricular power divided by the square of end-diastolic volume.

TL;DR: PWRU, divided by EDV2 provides a measure of contractile function that is little influenced by loading conditions and has potential for noninvasive clinical use.
Journal ArticleDOI

Mechanical Dyssynchrony in Dilated Cardiomyopathy With Intraventricular Conduction Delay as Depicted by 3D Tagged Magnetic Resonance Imaging

TL;DR: The extent of mechanical dyssynchrony in patients with dilated cardiomyopathy and intraventricular conduction delays is demonstrated and it is shown that pacing can restore synchronization and, thereby, improve function.
Journal ArticleDOI

Nitroxyl (HNO) a Novel Approach for the Acute Treatment of Heart Failure

TL;DR: These data show the functional efficacy of a novel, stable, pure HNO donor to enhance myocardial function and present first-in-man evidence for its potential usefulness in HF.
Journal ArticleDOI

Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase.

TL;DR: In this paper, the effect of β3-adrenergic receptor (AR) activation and downstream signaling of nitric oxide synthase (NOS) isoforms on the heart from failure and hypertrophy induced by pressure overload was investigated.
Journal ArticleDOI

Advanced glycation end product cross-linking: pathophysiologic role and therapeutic target in cardiovascular disease.

TL;DR: New pharmacologic agents that prevent AGE, break cross-links, or block AGE receptors reduce vascular and myocardial stiffness, inhibit atherosclerotic plaque formation, and improve endothelial function, and thus, heart failure.